文献速递肿瘤 PET/CT

受天然配体启发的肽用于c-MET靶向PET探针开发

Native Ligand-Inspired peptides for c-MET targeted PET probes development.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-06-16

本研究基于肝细胞生长因子(HGF)N端及kringle 1结构域设计三种c-MET靶向肽,经DOTA偶联和68Ga标记后,在体外和体内评估其作为PET探针的性能。其中[68Ga]Ga-DOTA-A-M8对c-MET亲和力高(IC50=5.43 nM),在HCT-116荷瘤模型中显示特异性高摄取,30分钟肿瘤摄取为2.91±0.20%ID/g,主要通过肾-膀胱途径清除,结论认为基于天然配体开发PET探针是有效且可推广的策略。

要点

  • 基于HGF的NK1结构域设计三种c-MET靶向肽并经68Ga标记。
  • [68Ga]Ga-DOTA-A-M8对c-MET亲和力IC50=5.43 nM,在HCT-116细胞显示特异性高摄取。
  • 小动物PET/CT中[68Ga]Ga-DOTA-A-M8在120分钟内清晰显影肿瘤,主要通过肾-膀胱途径清除。

核心结论

  • 本研究成功开发了一种新型c-MET靶向PET探针[68Ga]Ga-DOTA-A-M8,具有高肿瘤靶向能力和特异性。
  • 作者认为基于天然配体开发PET探针是有效且可推广的策略。

研究设计与样本

  • 从HGF的N端和kringle 1结构域(NK1:32-207氨基酸残基)设计三种c-MET靶向肽,与DOTA偶联后用[68Ga]GaCl3标记,得到[68Ga]Ga-DOTA-K1、[68Ga]Ga-DOTA-A-C5和[68Ga]Ga-DOTA-A-M8三种探针,并进行体外和体内评估。

主要发现

  • 三种PET探针中,[68Ga]Ga-DOTA-A-M8对c-MET亲和力高(IC50=5.43 nM),在c-MET高表达HCT-116细胞中显示特异性和高摄取。
  • 小动物PET/CT成像用[68Ga]Ga-DOTA-A-M8在120分钟内清晰显示肿瘤,对比度良好。
  • PET图像定量分析显示,注射后30分钟[68Ga]Ga-DOTA-A-M8在HCT-116模型的肿瘤摄取为2.91±0.20%ID/g。
  • 生物分布研究显示,注射后30分钟HCT-116肿瘤摄取在正常组为2.84±0.07%ID/g,在阻断组为0.54±0.09%ID/g。
  • 注射后30分钟肿瘤/肌肉、肿瘤/血液和肿瘤/肝脏比值分别为3.60±1.09、1.48±0.24和2.48±0.28;探针主要通过肾-膀胱途径清除。

关键数值与推荐

  • [68Ga]Ga-DOTA-A-M8对c-MET的IC50=5.43 nM。
  • 注射后30分钟HCT-116肿瘤摄取:正常组2.84±0.07%ID/g vs 阻断组0.54±0.09%ID/g。
  • 注射后30分钟肿瘤/肌肉、肿瘤/血液和肿瘤/肝脏比值分别为3.60±1.09、1.48±0.24和2.48±0.28。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Native ligand-derived peptides have significantly advanced the development of targeting ligands in radiopharmaceutical discovery and design. Herein, we report the first attempt to develop novel mesenchymal-epithelial transition factor (c-MET) targeted peptide positron emission tomography (PET) probes based on the endogenous biomolecule, hepatocyte growth factor (HGF). METHODS: Three c-MET targeted peptides were designed from the N-terminal and kringle 1 domain (NK1: 32-207 amino acid residues) of HGF. Then they were conjugated with chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and radiolabeled with [68Ga]GaCl3. The resulted [68Ga]Ga-labelled probes, [68Ga]Ga-DOTA-K1, [68Ga]Ga-DOTA-A-C5, and [68Ga]Ga-DOTA-A-M8 were evaluated in vitro and in vivo. RESULTS: Among three PET probes, [68Ga]Ga-DOTA-A-M8 exhibited a high affinity for c-MET (IC50 = 5.43 nM) and demonstrated specific and high uptake in c-MET highly expressing HCT-116 cells. Small animal PET/CT imaging clearly visualized the tumor with good contrast using [68Ga]Ga-DOTA-A-M8 over 120 min. Quantitative analysis of PET images revealed tumor uptake of [68Ga]Ga-DOTA-A-M8 at 30 min post-injection was 2.91 ± 0.20%ID/g in HCT-116 models. The probe was mainly cleared out through the kidney-bladder pathway. Biodistribution study showed HCT-116 tumor uptake of 2.84 ± 0.07%ID/g and 0.54 ± 0.09%ID/g in the normal and blocking mice group, respectively, at 30 min post-injection. The tumor-to-muscle, tumor-to-blood and tumor-to-liver ratios were 3.60 ± 1.09, 1.48 ± 0.24 and 2.48 ± 0.28, respectively, at 30 min. CONCLUSION: A novel c-MET-targeting PET probe, [68Ga]Ga-DOTA-A-M8, has been successfully developed in this study. It demonstrates high tumor-targeting capability and specificity. This study highlights developing PET probes based on native ligands is a powerful and generalizable strategy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Luo R, Tan B, Zhang Y, et al. Native Ligand-Inspired peptides for c-MET targeted PET probes development. Eur J Nucl Med Mol Imaging. 2025. PMID: 40522466. doi:10.1007/s00259-025-07403-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。